Optimizing Blood Pressure Control: A Randomized Comparative Trial of Losartan/Chlorthalidone vs. Losartan/Hydrochlorothiazide [0.03%]
优化血压控制的随机对照试验：厄贝沙坦氯噻酮与厄贝沙坦氢氯噻嗪的比较研究
Isabel E Rucker-Joerg,Ernesto G Cardona-Muñoz,Francisco G Padilla-Padilla et al.
Isabel E Rucker-Joerg et al.
Introduction: Cardiovascular diseases are a leading cause of global mortality, with hypertension as a major risk factor. Low control rates are often attributed to monotherapy, while evidence and clinical guidelines suppor...
Defibrillation Threshold Testing After ICD Implantation in Patients with Chronic Kidney Disease [0.03%]
慢性肾病患者植入ICD后的除颤阈值测试
Rohit J Timal,Lano Osman,Joris I Rotmans et al.
Rohit J Timal et al.
Introduction: Routine defibrillation threshold (DFT) testing at the time of implantable cardioverter-defibrillator (ICD) implantation is no longer recommended because testing did not improve shock efficacy or reduce arrhy...
Stressful Life Events and Heart Failure: A Mixed-Method Study to Analyze the Patient's Perspective [0.03%]
压力生活事件与心力衰竭：一项结合定性和定量研究方法分析患者的视角的研究
Dina Di Giacomo,Eleonora Cilli,Federica Guerra et al.
Dina Di Giacomo et al.
Introduction: The challenge in heart failure medical practice is to address the clinical and laboratory method integrations for the shared decision-making process in caring for patients and families. Furthermore, stressfu...
Impella Versus VA-ECMO for Patients with Cardiogenic Shock: Preliminary Cost-Effectiveness Analysis in the Italian Context [0.03%]
IMPELLA和VA-ECMO对于心源性休克患者的费用效益分析：意大利环境下的初步研究
Carla Rognoni,Vittoria Ardito,Dario La Fauci et al.
Carla Rognoni et al.
Introduction: Cardiogenic shock (CS) is a life-threatening failure of the heart to supply adequate blood, requiring immediate treatment. Although nowadays Impella® heart pumps and veno-arterial extra-corporeal membrane o...
The Atrial FibriLlatiOn Registry (FLOW-AF): Patient Characteristics, Treatment Patterns, and Outcomes in Egypt [0.03%]
心房纤维化登记注册(FLOW-AF)：埃及患者的特征、治疗模式和结果
Mohamed Sobhy,Magdy Abdelhamid,Adel Mohamed El Etriby et al.
Mohamed Sobhy et al.
Introduction: Real-world data on atrial fibrillation (AF) in the Middle East and North Africa (MENA) region, including Egypt, are sparse. The aim of the FLOW-AF registry was to evaluate the characteristics, treatment patt...
Rationale and Design of ANTHOLOGY: An ATTR Amyloidosis Real-World Evidence Program Aiming to Address Gaps in Amyloidosis Care [0.03%]
RATIONALE AND DESIGN OF ANTHOLOGY：AN ATTR AMYLOIDOSIS REAL-WORLD EVIDENCE PROGRAM AIMING TO ADDRESS GAP IN AMYLOIDOSIS CARE的rationale and design
Julian D Gillmore,Katrin Hahn,J Gustav Smith et al.
Julian D Gillmore et al.
Introduction: Patients with amyloid transthyretin (ATTR) amyloidosis typically experience rapid disease progression, poor treatment outcomes, irreversible loss of health-related quality of life (HRQoL), and premature mort...
ACEi and ARBs as Primary Prevention of Cancer Therapy-Related Cardiomyopathy in Patients Undergoing Chemotherapy with Anthracyclines: A Systematic Review and Meta-Analysis [0.03%]
血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂作为主要预防手段防止接受蒽环类药物化疗患者的癌症治疗相关心肌病：系统回顾与荟萃分析
Wissam Harmouch,Ravi Thakker,Alexander Dang et al.
Wissam Harmouch et al.
Introduction: Anthracyclines treat a myriad of malignancies; however, they are known to lead to cancer therapy-related cardiomyopathy (CTRC). Randomized controlled trials (RCTs) evaluating the role of angiotensin converti...
Cardiovascular Outcomes of Early LDL-C Goal Achievement in Patients with Very-High-Risk ASCVD [0.03%]
极高危ASCVD患者早期实现LDL-C目标的 cardiovascular 结局
Ah-Ram Kim,Ji Ye Han,Minkyoung Kim et al.
Ah-Ram Kim et al.
Introduction: Clinical trial evidence supports early low-density lipoprotein cholesterol (LDL-C) goal achievement in patients with atherosclerotic cardiovascular disease (ASCVD), but real-world evidence in Asia is lacking...
The Effect of Colchicine on Platelet Function Profiles in Patients with Stable Coronary Artery Disease: The ECLIPSE Pilot Study [0.03%]
秋水仙碱对稳定型冠心病患者血小板功能的影响：ECLIPSE 试验试点研究结果
Naveen Seecheran,Kathryn Grimaldos,Penelope McCallum et al.
Naveen Seecheran et al.
Introduction: This prospective, single-arm pharmacodynamic study assessed the effect of colchicine (COLC) [Strides Pharma UK Ltd, Watford, Hertfordshire, England] 0.5 mg administered orally once daily for 14 days on plate...